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Abstract: The majority of patients with gastrointestinal cancers are over the age of 65. This age group comprises the minority of the 
patients enrolled in clinical trials, and it is unknown whether older patients achieve similar results as younger patients in terms of 
­ survival­benefit­and­tolerability.­In­addition,­there­are­few­studies­specifically­designed­for­patients­over­65­years.­Subset­analyses­of­
individual trials and studies using pooled patient data from multiple trials provide some understanding on outcomes in older patients 
with gastrointestinal cancers. This article reviews the evidence on chemotherapeutic regimens in the elderly with colorectal, pancreatic, 
and gastroesophageal cancers, and discusses a practical approach to provide the best outcomes for older patients.
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Introduction
As our population ages, the treatment of older patients 
with cancer will become a more common part of oncol-
ogy practice. Unfortunately, the geriatric population 
has typically been underrepresented in clinical trials, 
representing only 25%–30% of study participants.1,2 
As a result, it is unclear if many of the advances in 
cancer treatment also apply to the elderly.
Data on studies in colorectal cancer indicate phy-
sicians  are  often  reluctant  to  give  elderly  patients 
chemotherapy or to enroll them in clinical trials.3,4 
Even after adjusting for comorbidities, performance 
status, and other treatment predictors, elderly patients 
are less likely to receive chemotherapy.4­If­they­do­
receive  palliative  or  adjuvant  chemotherapy,  it  is 
often at reduced doses and/or with fewer cycles of 
treatment. This may affect outcomes, as data from the 
Surveillance,­Epidemiology,­and­End­Results­(SEER)­
database suggest elderly patients who receive longer 
durations of 5-FU based chemotherapy have reduced 
mortality.5 There is also evidence that among patients 
with comorbidities, those who receive cancer treat-
ment survive longer.6
Many investigators have attempted to address the 
gap that exists between the treatment of younger and 
older patients with cancer. This review focuses on the 
available data regarding systemic therapy for elderly 
patients with gastrointestinal malignancies, including 
colorectal, pancreatic, and gastroesophageal cancers.
colorectal cancer
Colorectal­cancer­(CRC)­is­the­third­most­common­
cancer for both men and women, with 150,000 new 
diagnoses  each  year  and  50,000  deaths  per  year.7 
The  incidence  of  colorectal  cancer  increases  with 
each decade of life. The median age at diagnosis is 
71 years, and patients $65 years of age comprise 
67% all colorectal cancer diagnoses.8,9 While the data 
are fairly consistent for older patients with metastatic 
CRC­(mCRC),­whether­elderly­patients­benefit­from­
recent advances in the adjuvant setting remains an 
area of controversy.
Adjuvant therapy
The prior standard of care for adjuvant therapy for 
colorectal­cancer­was­5-fluorouracil­combined­with­
leucovorin­(5-FU/LV).­The­benefit­of­adjuvant­5-FU­
therapy in elderly patients is clear. Three   retrospective 
analyses documented improved survival with the use 
of  adjuvant  5-FU  therapy  compared  with  surgery 
alone.10–12
It­is­not­as­evident­if­elderly­patients­benefit­from­
the new standards in adjuvant therapy. Clinical trials 
have demonstrated that the addition of the chemo-
therapeutic­agent­oxaliplatin­significantly­improved­
outcomes­for­patients­with­stage­III­colon­cancer­
over­ 5-FU/LV­ alone.­ Oxaliplatin­ plus­ 5-FU/LV­
(or­capecitabine)­in­the­adjuvant­setting­improves­
3-year­disease-free­survival­(DFS)13–15 and overall 
survival­(OS).13 Thus, the combination of oxalipla-
tin­and­5-FU/LV­(or­capecitabine)­has­become­the­
standard­of­care­in­the­adjuvant­setting­for­stage­III­
disease.
Due  to  the  lack  of  randomized  trials  aimed 
­ specifically­at­the­elderly,­much­of­the­data­on­the­
use  of  oxaliplatin  in  the  elderly  comes  from  sub-
set  analyses  of  large  randomized  trials  or  pooled 
analyses­­ involving­multiple­trials.­One­of­the­most­
detailed  retrospective  analyses  evaluating  oxalipla-
tin use in the elderly was a pooled analysis of 1,567 
patients  $70  years  from  clinical  trials  undergoing 
treatment­ with­ 5-FU/LV/oxaliplatin­ (FOLFOX)­ in­
either the adjuvant or advanced setting.16 Toxicities 
were fairly similar between older and younger patients, 
with the exception of neutropenia and thrombocyto-
penia­being­significantly­higher­in­patients­$70 years. 
  Additionally,  the  mortality  at  60  days  from  start-
ing­therapy­was­not­significantly­different­between­
young­and­older­patients­(1.1%­vs.­2.3%,­P =­0.2).­
Neither­DFS­nor­OS­differed­significantly­between­
patients ,70 years and those $70­years.­On­multi-
variate analysis, age was not associated with likeli-
hood  of  response  among  patients  in  the  advanced 
disease   trials. Dose intensity did not differ between 
older and younger patients, although older patients 
did receive fewer cycles of therapy.
The results from this pooled analysis suggest that 
oxaliplatin-based therapy can be administered with 
only­mildly­increased­toxicity.­The­data­also­confirm­
that­elderly­patients­can­benefit­from­these­therapies­
similarly­to­younger­patients­in­terms­of­DFS­and­OS.­
However, the majority of the patients in this study 
were­treated­in­the­advanced­setting.­In­addition,­all­
European­trials,­which­made­up­a­significant­percent-
age of the patients in the pooled analysis, did not 
include patients over the age of 75.Chemotherapy for older patients
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Studies­of­patients­receiving­therapy­purely­in­the­
adjuvant­setting­have­led­to­conflicting­data­regarding­
the­benefit­of­oxaliplatin­in­elderly.­Subset­analyses­of­
the­Multicenter­International­Study­of­Oxaliplatin/5-
Fluorouracil/Leucovorin­in­the­Adjuvant­Treatment­
of­Colon­Cancer­(MOSAIC)­and­the­National­Sur-
gical­Adjuvant­Breast­and­Bowel­Project­(NASBP)­
C-07­trials­demonstrated­that­the­benefit­of­adjuvant­
oxaliplatin-based therapy for elderly patients is not 
statistically­significant.13,15­In­contrast,­the­N016968­
trial,­ which­ compared­ bolus­ 5-FU/LV­ to­ a­ combi-
nation­ of­ capecitabine­ and­ oxaliplatin­ (XELOX)­
showed­that­elderly­patients­received­a­benefit­in­a­
short­term­endpoint­of­3-year­DFS,­long­term­data­
from the N016968 trial remain pending.14
A pooled analysis of 12,669 patients from 6 ran-
domized­trials­evaluated­the­impact­of­age­on­the­effi-
cacy­of­recently­tested­regimens­(oxaliplatin-based,­
irinotecan-based,­and­oral­­ fluoropyrimidine-based).17 
Seventeen­ percent­ of­ the­ patients­ (n­ =­ 2170)­
were $70 years of age. Newer adjuvant therapies were 
not­associated­with­a­significant­treatment­benefit­in­
patients $70 compared to those ,70­years­(Table­1).­
This­was­consistent­when­specifically­evaluating­tri-
als  involving  oxaliplatin  and  trials  containing  oral 
fluoropyrimidines.­There­was­no­increase­in­deaths­in­
the­first­6­months­of­adjuvant­therapy­between­exper-
imental and control arms overall or among different 
types of therapy. The results of this analysis raise 
concern about the use of oxaliplatin-based regimens 
in unselected elderly patients.
A­SEER-Medicare­based­study­also­evaluated­the­
use of several regimens in 8,294 patients .65 years 
receiving­ adjuvant­ therapy­ for­ stage­ III­ colon­
  cancer.18 The analysis included patients treated with 
5-FU/LV­alone­(n­=­7,726),­oxaliplatin-based­therapy­
(n­=­816),­and­irinotecan-based­therapy­(n­=­382).­
After adjusting for multiple factors, oxaliplatin-based 
therapy was associated with improved overall sur-
vival­(HR:­0.566;­95%­CI:­0.370–0.866;­P =­0.0087)­
and­­ colorectal­cancer-specific­survival­(HR:­0.385;­
95%­CI:­0.208–0.712;­P =­0.0023)­when­compared­
to­5-FU/LV­alone.­Neither­OS,­nor­colorectal­can-
cer­ specific­ survival­ differed­ between­ irinotecan­
regimens­and­5-FU/LV­alone.­It­must­be­recognized­
that   population-based studies are subject to potential 
selection bias as in general healthier patients are more 
likely to receive the more aggressive treatment.
The decision whether to treat elderly patients with 
oxaliplatin-based  adjuvant  therapy  will  become  a 
growing problem over the next two decades, when 
the amount of people in the population over age 65 is 
expected to increase dramatically. This will result in 
greater numbers of patients requiring adjuvant ther-
apy for resected colorectal cancer, and thus the role of 
oxaliplatin-based therapy in this situation needs to be 
further­defined.­Conflicting­results­of­the­above­stud-
ies gives us the opportunity to individualize therapy 
for­patients.­A­fit­patient­over­65­with­low­comorbid-
ity may be a candidate of oxaliplatin-based adjuvant 
therapy. However, elderly patients with a poorer per-
formance status and/or comorbidities may be more 
appropriate­for­5-FU/LV­or­capecitabine­alone.
Therapy for advanced/metastatic 
disease
In­contrast­to­the­adjuvant­setting,­multiple­studies­
consistently show oxaliplatin-based therapy improves 
outcomes­for­the­elderly­with­mCRC.19–22 Data from 
these and other trials also demonstrate that toxici-
ties and tolerability were similar between older and 
younger patients.16,23­The­reasons­why­the­benefit­of­
oxaliplatin therapy for elderly patients with advanced 
disease is not as evident in the adjuvant setting are 
unknown.
Strategies­can­be­applied­to­reduce­or­minimize­
toxicity­from­the­commonly­used­FOLFOX­regimen.­
Table 1. Efficacy of adjuvant therapy according to age.17
,70 $70 P value
HR experimental arm vs. control arm 
Efficacy in the overall population (all trials)
DFS 0.85 (0.80,0.91) 1.11 (0.97,1.27) 0.005
OS 0.86 (0.79,0.92) 1.14 (0.98,1.32) 0.005
TTR 0.84 (0.79,0.91) 1.13 (0.97,1.32) 0.004
Efficacy of oxaliplatin-based therapy vs.  
intravenous 5-FU/LV
DFS 0.77 (0.68,0.86) 1.04 (0.80,1.35) 0.016
OS 0.81 (0.71,0.93) 1.19 (0.90,1.57) 0.037
TTR 0.76 0.92 (0.69,1.23) 0.21
Efficacy of oral fluoropyrimidine therapy  
vs. intravenous 5-FU/LV
DFS 0.89 (0.79,1.0) 1.13 (0.90,1.42) 0.1
OS 0.87 (0.76,1.0) 1.17 (0.92,1.48) 0.06
TTR 0.90 (0.79,1.0) 1.16 (0.90,1.50) 0.13
Abbreviations: DFS, Disease-free survival; OS, Overall survival; TTR, 
Time to tumor recurrence.Hubbard et al
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For­ instance,­ the­ “modified”­ FOLFOX­ regimens­
often omit the 5-FU bolus to minimize side effects, 
especially the degree of neutropenia and mucositis. 
Another­option­is­to­use­the­“stop-and-go”­strategy­
as­ in­ the­ OPTIMOX­ trials.24  With  disease  stabil-
ity,­6–8­cycles­of­FOLFOX­(with­or­without­beva-
cizumab)­can­be­followed­by­maintenance­5-FU­or­
capecitabine­(and­bevacizumab).­Upon­progression­
oxaliplatin  can  be  reintroduced  or  an  alternative, 
irinotecan-based  regimen  can  be  used.  This  strat-
egy­does­not­compromise­efficacy,­and­reduces­the­
incidence of grade 3/4 neurotoxicity, and potentially 
maximizes­benefit­from­oxaliplatin­therapy.
Capecitabine­plus­oxaliplatin­(XELOX)­was­found­
to be non-inferior to 5-FU plus oxaliplatin in a large 
randomized­phase­III­trial­in­terms­of­progression-
free and overall survival.25 To determine whether this 
regimen was appropriate for elderly patients, an anal-
ysis­of­a­phase­II­trial­examined­outcomes­of­when­
XELOX­was­used­in­patients­$65­with­mCRC.22­Of­
96 patients on the trial, 44 were $65­years.­Older­
patients­received­a­median­of­8­cycles­of­XELOX.­
Response­rates­(RR)­(58%­and­52%),­time­to­tumor­
progression­ (TTP)­ and­ OS­ were­ similar­ between­
younger­and­older­patients­(P .­0.5),­and­there­were­
no­ significant­ differences­ in­ toxicity.­ A­ separate­
phase­II­trial­evaluating­XELOX­in­the­elderly­with­
mCRC­also­concluded­it­was­a­safe­and­effective­reg-
imen to use in selected elderly patients.26
Irinotecan-based­therapy­has­also­become­a­stan-
dard­for­mCRC,­typically­when­combined­with­5-FU/
LV­(FOLFIRI).­Two­phase­III­trials­have­investigated­
the­combination­of­FOLFIRI­compared­to­5-FU/LV,­
and­both­demonstrated­improved­RR­and­PFS­for­the­
triple combination regimen.27,28 The trial by Douillard 
et al27­reported­an­improved­OS­17.4­months­for­the­
irinotecan  containing  regimen  versus  14.1  months 
for­the­5-FU/LV­arm­(P =­0.031).­Köhne­et­al28 did 
not­report­a­significant­increase­in­OS­for­the­triple­
combination­regimen­when­compared­to­the­5-FU/LV­
arm, but this was felt due to the increased availability 
of second and third line therapies. Patients over the 
age­of­70­appear­to­achieve­similar­benefits­as­well­as­
similar toxicity rates as younger individuals   receiving 
  irinotecan-based therapy.29
Triple  drug  regimens  have  been  examined  in 
advanced­CRC.­Falcone­et­al30­reported­a­significant­
improvement­in­OS­(22.6­months­vs.­16.7­months;­
HR­ 0.70,­ P  =­ 0.032)­ with­ FOLFOXIRI­ when­
compared­ to­ FOLFIRI­ alone.­ This­ trial­ purposely­
selected  patients  to  exclude  elderly  and  frail  indi-
viduals. A  separate  study  comparing  these  2  regi-
mens­included­older­patients­(median­age­66;­56%­
.­65­years)­and­poorer­PS­(36%­ECOG­PS­of­0).31 
Compared the Falcone study, the doses were lower, 
there­was­no­difference­in­OS,­and­elderly­patients­
had­significantly­more­toxicity.
More  recently,  monoclonal  antibodies  directed 
against­the­epidermal­growth­factor­receptor­(EGFR),­
cetuximab and panitumumab, have been developed. 
When used as a single agent in the last line setting 
or in combination with cytotoxic chemotherapy, the 
EGFR­inhibitors­provide­benefit­in­the­metastatic­set-
ting, but not the adjuvant setting.32–34­In­an­analysis­
of 56 patients age $70­years,­the­efficacy­and­toler-
ability appeared similar between younger and older 
patients.35 These agents provide no survival advan-
tage­to­patients­with­KRAS­mutant­tumors,­and­in­
fact, have the potential to add harm to this subset of 
patients.36,37 Therefore, all colorectal tumors should 
be­tested­for­KRAS­mutation­status­prior­to­adminis-
tering­EFGR­inhibitors.
Bevacizumab is another targeted therapy showing 
benefit­in­advanced­colorectal­cancer.38–40 However, 
the use of bevacizumab in elderly patients should be 
carefully considered. A 1.8 fold increased risk of arte-
rial­thrombotic­events­(ATE)­was­seen­with­the­use­of­
bevacizumab in patients .65 years, an effect mag-
nified­with­a­prior­history­of­ATEs.41 Data from the 
Bevacizumab­Regimens:­Investigation­of­Treatment­
Effects­and­Safety­(BRiTE)­registry­confirmed­this­
risk in patients .75 years.42­On­the­other­hand,­elderly­
patients did not have an increased risk of gastrointes-
tinal bleeding/perforation or hypertension compared 
with a younger cohort. Elderly patients must be coun-
seled on the increased risk of ATEs, and for those with 
prior ATE, bevacizumab is contraindicated.
Newer­ advances­ in­ the­ treatment­ of­ mCRC­
should  not  be  withheld  from  older  patients  based 
on  age  alone.  Multiple  studies  indicate  selected 
patients $65­years­can­achieve­similar­benefits­to­
oxaliplatin-  and    irinotecan-based  therapy  as  well 
as  targeted  therapy  without  substantial  addition  in 
­ toxicity.­One­must­use­caution­in­those­with­poorer­
PS­or­multiple­comorbidities,­as­these­patients­are­a­
different   population than those typically enrolled on Chemotherapy for older patients
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  clinical trials.   Fluoropyrimidine therapy alone may 
be more appropriate for such individuals.
pancreatic cancer
Pancreatic cancer is a disease of older patients. The 
median­age­at­diagnosis­in­the­United­States­is­72­years,­
and over 68% of those diagnosed are $65 years of 
age.43 This section will discuss systemic therapy for 
older patients in the adjuvant, locally advanced, and 
metastatic settings.
Adjuvant therapy
Two agents are currently used for adjuvant therapy 
after­resection­of­pancreatic­cancer:­5-FU­or­gemcit-
abine.­The­ESPAC-1­trial­demonstrated­a­small,­but­
significant­survival­benefit­for­5-FU­therapy­versus­
those who did not receive chemotherapy, with median 
survivals of 19.7 months and 14.0 months respectively 
(HR­0.66­[95%­CI­0.52–0.83],­P =­0.0005).44 The sub-
sequent­CONKO-1­trial­demonstrated­a­significant­
increase­in­PFS­and­OS­for­patients­receiving­gem-
citabine versus observation alone.45 After extended 
follow-up,­the­median­OS­was­22.8­months­in­the­
gemcitabine arm and 20.2 months in the   observation 
arm­(P =­0.005),­with­estimated­survival­at­5­years­of­
21.0% and 9.0% respectively.
In­the­ESPAC-3­trial­patients­with­resected­pancre-
atic cancer were randomized to receive bolus 5-FU/
LV­ (Mayo­ Clinic­ regimen)­ versus­ ­ gemcitabine.46 
The median age of patients on this trial was 63 years 
(range­31–85­years).­Median­survival­was­similar­
between­the­5-FU/LV­arm­and­the­gemcitabine­arm,­
23.0­months­and­23.6­months­respectively­(P =­0.39).­
Quality­of­life­(QOL)­did­not­differ­between­the­2­
treatment­arms,­but­there­were­significantly­higher­
rates of adverse events in the 5FU group. 14% of 
patients had serious AEs in the 5-FU group, with 
higher rates of grade 3/4 stomatitis, but hematologic 
toxicities  were  more  common  in  the  gemcitabine 
arm. Age was not a prognostic factor for survival. 
Given­the­lower­rates­of­adverse­events­with­gemcit-
abine, it would appear to be a more   reasonable option 
for elderly patients.
Studies­investigating­the­use­of­concurrent­chemo-
radiation therapy in the adjuvant setting have yielded 
conflicting­results­regarding­the­survival­benefit­with­
the  addition  of  radiation  therapy.47–50  Concurrent 
chemoradiation therapy is often utilized in the adjuvant 
setting when there is evidence of nodal involvement 
detected at the time of surgery. The aforementioned 
studies did not include subset analyses for tolerability 
or survival outcomes in elderly patients. However, we 
might be able to extrapolate from data on the use of 
concurrent chemoradiation therapy in elderly patients 
with locally advanced, unresectable pancreatic cancer 
(see­below).
Locally advanced disease
Concurrent chemoradiation therapy became a stan-
dard  for  locally  advanced,  unresectable  pancreatic 
cancer after it was shown to improve 1-year survival 
by 30% over radiation therapy alone.51 A small ret-
rospective  analysis  evaluated  outcomes  of  patients 
undergoing chemoradiation therapy with protracted 
5-FU­ infusion­ (200­ mg/m2/day)­ along­ with­ radia-
tion­therapy­(50.4­Gy­in­28­fractions­over­5.5­weeks)­
according­to­age:­,70­years­(n­=­39)­or­$70 years 
(n­=­19).52­There­were­no­significant­differences­in­
severe toxicity, response rates or incidence in treat-
ment­­ discontinuation.­Median­OS­was­slightly­higher­
among­the­older­patients­(11.3­months)­versus­younger­
patients­(9.5­months),­likely­a­reflection­of­higher­
baseline performance status in the older group. This 
small study provides evidence that selected elderly 
patients can tolerate concurrent 5-FU-based chemo-
radiation therapy as well as younger patients.
Miyamoto et al53 reported a series of 42 patients 
.75 years of age who received chemoradiation ther-
apy­either­as­adjuvant­or­definitive­therapy­for­pan-
creatic  cancer.  The  study  included  3  patients  who 
received both 5-FU and gemcitabine and 2 patients 
who­ received­ capecitabine­ as­ radiosensitizer;­ the­
remaining  37  patients  received  5-FU.  The  median 
OS­was­8.6­months­in­the­inoperable­patients­and­
20.6 months for those in the adjuvant therapy group, 
similar to historic controls. Nausea, pain, and fail-
ure to thrive were the most common toxicities dur-
ing treatment. Hospitalization occurred in 8 patients 
(19%),­7­patients­(18%)­had­an­emergency­room­visit,­
and­9­patients­(21%)­did­not­complete­therapy.
Metastatic disease
The pivotal trial reported by Burris et al54 established 
the role of gemcitabine for patients with advanced 
pancreatic cancer. Patients were randomized to receive 
gemcitabine­versus­5-FU­(administered­at­500­mg/m2 Hubbard et al
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over­30­minutes­without­LV).­There­was­a­significant­
OS­benefit­in­the­gemcitabine­arm­with­a­median­sur-
vival of 5.6 months compared to 4.4 months in the 
5-FU­arm­(P =­0.0025),­and­the­1-year­survival­rate­
was 18% versus 2%, respectively. While the differ-
ence in median survival was not dramatic, patients in 
the­gemcitabine­arm­had­a­significant­improvement­
in­clinical­benefits,­pre-defined­as­an­improvement­in­
performance status, opioid requirements and weight 
loss­(23.8%­vs.­4.8%).
We­can­gain­insight­on­toxicities­specifically­in­the­
elderly with gemcitabine from a small retrospective 
study of 39 patients $70 years who received gem-
citabine 1000 mg/m2 weeks 1–3 of a 4 week cycle 
for advanced pancreatic cancer.55 Fifty-nine percent 
of patients received 100% of planned dose-intensity. 
Grade­3–4­adverse­events­were­most­commonly­neu-
tropenia­(38%),­thrombocytopenia­(28%),­and­ane-
mia­(18%).­The­median­PFS­was­7­months­and­OS­
was 10 months. The authors concluded that selected 
elderly­ patients­ could­ receive­ similar­ benefits­ to­
younger patients.
Multiple agents have been combined with gemcit-
abine in attempts to improve outcomes for patients 
with metastatic pancreatic cancer. The only agent that 
has­demonstrated­a­survival­benefit­is­erlotinib.­In­a­
phase­III­trial,­patients­were­randomized­to­gemcit-
abine plus erlotinib versus gemcitabine alone.56 The 
OS­was­6.24­months­in­the­combination­arm­versus­
5.91­ months­ alone­ (HR­ 0.82;­ 95%­ CI­ 0.69–0.99;­
P =­0.038).­Efficacy­and­toxicity­was­not­evaluated­
by­age.­However,­due­to­the­minimal­survival­benefit,­
it is generally felt the increase in toxicity and cost 
does not warrant the routine use of erlotinib, particu-
larly in the elderly population.
Oxaliplatin­ has­ also­ shown­ activity­ in­ meta-
static pancreatic cancer in the second-line   setting.57 
  Extrapolating  from  experience  among  elderly 
patients  with  colorectal  cancer,  one  would  expect 
that  oxaliplatin  could  safely  be  administered  to 
patients $65 years. However, the performance status 
of patients with metastatic pancreatic cancer typically 
declines­much­quicker­than­mCRC,­so­extra­caution­
must be used in this setting. The triple drug combina-
tion regimen using 5-FU, irinotecan and oxaliplatin 
(­ FOLFIRINOX),­ albeit­ highly­ active,­ is­ likely­ too­
toxic to be recommended for standard use in elderly 
patients with pancreatic cancer.58
Gastroesophageal cancers
Patients $65 years of age make up 60.9% and 63.6% 
of esophageal and gastric cancers respectively. For 
the general population, there is clear evidence that 
chemotherapy, whether alone or in combination with 
radiation therapy, improves survival in patients with 
gastroesophageal  cancers  over  surgery  alone.59–63 
  Preoperative, perioperative, and postoperative regi-
mens with or without radiation therapy have been 
studied.  The  following  discussion  addresses  each 
approach as it relates to treating the elderly.
Perioperative therapy for gastric cancer
The­ Medical­ Research­ Council­ Adjuvant­ Gastric­
Infusional­ Chemotherapy­ (MAGIC)­ trial­ random-
ized patients with operable gastric cancer to receive 
three­ cycles­ of­ ECF­ (epirubicin,­ cisplatin,­ 5-FU)­
before  and  after  surgery,  versus  surgery  alone.61 
Patients in the chemotherapy arm had a 5-year sur-
vival of 36.3% versus 23% in the surgery alone arm, 
with­ a­ HR­ for­ death­ of­ 0.74­ (95%­ CI­ 0.59–0.93;­
P =­0.009).­The­median­age­of­patients­on­the­trial­
was­ 62­ years­ (range­ 23–85­ years),­ and­ 20%­ of­
patients were .70 years. The survival results were 
independent of age, with patients .70­years­benefit-
ting as much as those ,70 years. Toxicity was not 
evaluated based on age. Postoperative complications 
did not differ between the two groups, but only half 
of the patients received chemotherapy after resection 
mainly due to progression/early death, complications, 
or patient refusal.
Adjuvant therapy for gastric cancer
Despite many clinical trials, there is no clear adju-
vant  therapy  standard  for  gastric  cancer,  although 
meta-analyses have concluded adjuvant therapy does 
provide­ benefit.64–66  A  recent  large  meta-analysis 
from­the­Global­Advanced/Adjuvant­Stomach­Tumor­
Research­ International­ Collaboration­ ­ (GASTRIC)­
Group­ included­ 17­ randomized­ trials­ and­ 3838­
patients.67­ The­ GASTRIC­ investigators­ found­ that­
adjuvant therapy for gastric cancer was associated 
with­improved­survival­(HR­0.82,­95%­CI­0.75–0.9,­
P ,­0.001).­There­appears­to­be­the­greatest­bene-
fit­from­5-FU­based­therapy,­even­as­monotherapy.­
Although­there­was­not­a­specific­analysis­related­to­
age,­it­is­likely­that­older­patients­fit­enough­for­a­clin-
ical­trial­do­stand­to­benefit­from­adjuvant­therapy,­Chemotherapy for older patients
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even if they are not candidates for combination ther-
apy regimens.
The­ Intergroup­ trial­ 0116­ randomized­ patients­
to receive adjuvant 5-FU for one cycle followed by 
chemoradiation followed by 2 more cycles of 5-FU 
versus surgery alone.62 Median survival was superior 
in the experimental arm compared to surgery alone, 
36 months and 27 months respectively, P = 0.005. The 
median age on the trial was 60 years in the treatment 
arm­(range­25–87)­and­59­years­in­the­control­arm­
(range­23–30).­The­effects­of­treatment­were­indepen-
dent of age, however there was no toxicity analysis 
in relation to age. Hematologic toxicities occurred in 
54% of patients and gastrointestinal toxicity in 33% 
of  patients. This  trial  was  criticized  because  more 
than half the patients received less than a D1 resec-
tion, and it remains uncertain if chemotherapy would 
have improved survival had adequate resection been 
performed on every patient. This regimen is not com-
monly­utilized­outside­of­the­US.
A­ large,­ randomized­ phase­ III­ trial­ from­ Japan­
demonstrated­a­survival­benefit­for­S-1,­another­oral­
fluoropyrimidine,­ over­ surgery­ alone.63  Three-year 
OS­was­80.1%­in­the­S-1­arm­compared­to­70.1%­in­
the­surgery­alone­arm­(HR­0.68,­95%­CI­0.52­to­0.87;­
P =­0.003).­The­most­common­adverse­events­with­
S-1­were­anorexia­(6.0%),­nausea­(3.7%),­and­diar-
rhea­(3.1%).­Due­to­differences­in­tolerability­in­non-
Asian­patients,­S-1­has­not­been­utilized­in­­ Western­
countries.
Preoperative therapy for esophageal 
cancer
In­general,­the­trend­has­been­to­utilize­preoperative­
therapy in locally advanced adenocarcinomas of the 
esophagus and gastroesophageal junction, based on 
results­of­several­phase­III­trials.68,69 The advantage 
to this approach is therapy prior to surgical resec-
tion­is­more­feasible­than­after­resection.­In­addi-
tion, preoperative therapy can downstage the tumor 
as well as potentially address any micrometastatic 
disease.
Data would suggest that elderly individuals have 
the­potential­to­benefit­from­this­approach­as­much­
as younger individuals, with slightly more toxicity. 
Rice­et­al70 reported a retrospective study evaluat-
ing patients with esophageal cancer $70 years who 
did­(n­=­35)­or­did­not­(n­=­39)­receive­preoperative­
chemoradiotherapy compared to patients ,70 years. 
The  chemotherapy  used  was  most  commonly 
cisplatin/5-FU­or­a­taxane.­The­efficacy­of­therapy­did­
not differ between younger or older patients, with no 
difference­in­1-­or­3-year­survival.­Older­age­(.70)­
was­not­a­predictor­in­postoperative­mortality.­Older­
patients had greater incidence of perioperative blood 
transfusions and postoperative atrial arrhythmias.
For  those  patients  who  are  not  candidates  for 
cisplatin/5-FU, carboplatin and paclitaxel are alter-
native­radiosensitizing­agents­with­OS­benefit­over­
surgery alone and an acceptable­toxicity­profile,­in­par-
ticular for patients with squamous cell carcinomas.71
Treatment for advanced/metastatic 
gastroesophageal cancer
A­meta-analysis­of­randomized­phase­II­and­III­tri-
als in advanced gastric cancer clearly demonstrated 
chemotherapy  improves  survival  in  advanced  gas-
troesophageal  cancer.72  Multiple  agents  including 
platinums,­ fluoropyrimidines,­ anthracyclines,­ tax-
anes, and irinotecan show activity. The trend over the 
years has gone from single agent to doublet to trip-
let chemotherapy regimens. As more agents are used 
concomitantly, survival has improved at the price of 
increased toxicity.
Three-drug  regimens  became  a  new  standard 
based­on­the­phase­III­trial­V325­that­demonstrated­a­
survival­benefit­over­for­docetaxel­and­cisplatin­plus­
fluorouracil­ (DCF)­ over­ cisplatin­ plus­ 5-FU­ (CF)­
alone.73­Patients­in­the­DCF­arm­had­a­median­OS­of­
9.2 months, compared to 8.6 months in the CF arm 
(P =­0.02).­The­2-year­survival­rate­of­18%­in­the­
experimental arm established DCF as a new standard. 
The­small­improvement­in­OS­came­with­significantly­
higher­ rates­ of­ grade­ III/IV­ neutropenia­ (82%­ vs.­
57%),­diarrhea­(19%­vs.­8%),­and­lethargy­(19%­vs.­
14%).­In­addition,­50%­of­patients­were­taken­off­
therapy  due  to  adverse  events  or  patient  refusal. 
Elderly patients were very underrepresented in this 
trial, with the median age of participants 55 years. 
Given­the­high­rates­of­hematologic­toxicities­and­
small­survival­benefit,­it­remains­unclear­if­this­regi-
men­will­be­tolerable­in­the­elderly­patient.­Modified­
DCF­regimens,­such­as­reported­by­Shah­et­al74 are 
associated with reduced rates of neutropenia without 
compromising­efficacy­and­may­be­more­appropriate­
for older adults.Hubbard et al
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The­ goal­ of­ the­ Randomized­ ECF­ for­ adju-
vant and locally advanced esophagogastric cancer 
(REAL-2)­study­was­to­establish­the­non-inferior-
ity­of­capecitabine­(X)­to­5-FU­(F)­and­oxaliplatin­
(O)­to­cisplatin­(C)­when­combined­with­epirubicin­
(E).75 Patients were randomized in a 2 by 2 design 
to­receive­ECF,­ECX,­EOF­and­EOX.­The­median­
survival  in  the  four  study  arms  was  9.9  months, 
9.9  months,  9.3  months  and  11.2  months  respec-
tively. This trial established the non-inferiority of 
capecitabine­(to­5-FU)­ and­ oxaliplatin­(to­cispla-
tin),­a­result­that­has­enhanced­the­options­available.­
Importantly,­ the­ oxaliplatin-containing­ arms­ had­
less neutropenia, alopecia, renal toxicity, and throm-
boembolism,­but­greater­neuropathy­and­diarrhea.­In­
contrast­to­the­V325­trial,­REAL-2­included­older­
patients;­the­median­age­varied­between­61­and­65­
among the treatment arms.
There­have­not­been­prospective­trials­specifically­
evaluating outcomes in the elderly with esophagogas-
tric cancers. However there are two pooled analyses 
of data from clinical trials examining outcomes in 
the­elderly.­The­first­includes­257­patients­$70 years 
from­3­clinical­trials.­The­incidence­of­grade­III/IV­
toxicities,  response  rates,  and  overall  survival  did 
not­differ­significantly­between­patients­$70 years 
compared to those ,70 years. Another analysis of 
367 patients with incurable esophagogastric cancers 
within­8­consecutive­first­line­therapy­trials­through­
North­ Central­ Cancer­ Treatment­ Group­ (NCCTG)­
from 1987 to 2006 included 154 patients $65 years 
of age.76 Despite having poorer performance status, 
there was also no difference in median survival or 
PFS­between­older­and­younger­patients­respectively.­
In­this­analysis,­there­were­higher­rates­of­adverse­
events  including  grade  3+  leucopenia,  stomatitis, 
fatigue­and­grade­4­vomiting.­In­addition,­there­were­
higher rates of grade 4+­events­in­the­elderly­(40%­vs.­
28%, P =­0.02).
S-1­has­shown­activity­in­patients­with­advanced­
gastric cancer both as a single agent and in combi-
nation­with­cisplatin­or­irinotecan­among­Japanese­
patients.63,77–79 However, when tested in the Western 
patients,­S-1­combined­with­cisplatin­did­not­show­a­
survival advantage over 5-FU plus cisplatin.80   Therefore, 
S-1­has­not­been­approved­for­use­in­the­US.
The­Trastuzumab­for­Gastric­Cancer­(ToGA)­trial­
demonstrated­ clear­ benefit­ of­ targeted­ therapy­ for­
gastric  cancer  and  established  trastuzumab  as  the 
new­standard­for­HER2+ disease.81 Twenty percent 
of­patients­on­this­trial­had­GE­junction­tumors.­Tras-
tuzumab,­when­added­to­5-FU­plus­cisplatin,­signifi-
cantly­improved­median­OS­over­5-FU­plus­cisplatin­
alone 13.8 months versus 11.1 months respectively 
(HR­0.74;­95%­CI­0.60–0.91;­P =­0.0046).­There­was­
no difference in adverse events between the 2 arms, 
with  nausea,  vomiting,  and  neutropenia  being  the 
most­common­toxicities.­Cardiac­dysfunction­(defined­
as a $10% drop in left ventricular systolic function 
to ,50%)­occurred­in­11­of­237­patients­(5%)­in­
the trastuzumab arm compared to 2 of 187 patients 
(1%)­ with­ chemotherapy­ alone,­ but­ these­ changes­
were clinically asymptomatic. The average age of the 
patients on trial was approximately 59 years. Age was 
a­prespecified­sub-group­of­patients­evaluated­for­OS,­
the­HR­for­survival­0.66­(95%­CI­0.49–0.88),­indicat-
ing­a­significant­benefit­for­patients­$60 years of age. 
Trastuzumab­can­be­used­without­adding­significant­
toxicity, however careful monitoring for systolic dys-
function is recommended.
Although­multiple­clinical­trials­trying­to­define­
optimal  management  for  gastroesophageal  cancers 
have left us with unanswered questions, they have 
also provided evidence for a variety of agents and 
regimens that have activity in this disease. This gives 
oncologists the ability to tailor treatment to the par-
ticular needs of each elderly patient.
conclusions
The data reviewed in this article provide evidence 
that  elderly  patients  with  gastrointestinal  cancers 
can­benefit­from­systemic­therapy.­The­decision­to­
select patients for particular regimens should not be 
based­solely­on­age­alone.­Likewise,­agents­that­pro-
long survival should not automatically be withheld 
from patients with imperfect performance status or 
  comorbidity. Each individual should be assessed for 
an appropriate regimen. Most importantly, the deci-
sion of how to treat elderly patients must incorporate 
goals and preferences of the patient after a careful 
discussion­of­risks­and­benefits.
Several­tools­exist­that­may­be­utilized­to­guide­
treatment decisions for the older patient with can-
cer such as geriatric assessment scores, comorbidity 
indices, frailty indices, and prognostic indices for sur-
vival. These may help the clinician to better estimate Chemotherapy for older patients
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the patient’s physical and mental condition to deter-
mine­if­the­potential­survival­benefits­are­worth­the­
potential toxicity, however they may not be easy to 
incorporate  in  a  busy  clinical  practice.  Efforts  are 
ongoing to assess shorter screening tools to identify 
those geriatric patients who may not tolerate standard 
therapy.82
In­order­to­improve­upon­our­knowledge­of­how­
to  treat  older  patients  with  cancer,  these  patients 
should  be  enrolled  in  clinical  trials  with  more 
­ frequency.­In­addition,­there­is­a­need­for­clinical­tri-
als need to be designed for this patient population. An 
­ upcoming­Intergroup­study­will­evaluate­oxaliplatin/
fl ­uoropyrimidine­ therapy­ plus­ bevacizumab­ versus­
fluoropyrimidine­plus­bevacizumab­as­first-line­ther-
apy­in­elderly­patients­with­mCRC.­This­trial­incor-
porates as a component the prospective validation of 
a frailty index. Future trials should also be designed 
to incorporate an assessment of outcomes in relation 
to age to provide further guidance on whether the reg-
imen is appropriate for elderly patients.
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